ASCO 2016 Update: Immunotherapy and Melanoma

Harold Burstein, Elizabeth Buchbinder

Harold J. Burstein, MD, PhD (right), discusses the latest immunotherapy research with Elizabeth Buchbinder, MD (left).

As one of the hottest topics in cancer research today, immunotherapy took center stage at the 2016 American Society of Clinical Oncology meeting in Chicago. Harold J. Burstein, MD, PhD, a breast oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, recently sat down with other oncologists to break down some of the meeting’s more important findings.

Below, he talks with Elizabeth I. Buchbinder, MD, a melanoma specialist, about some of the research related to pembrolizumab (Keytruda), which was used to treat former President Jimmy Carter, and other immunotherapy news.

Watch additional ASCO video updates and learn about other important research presentations.

Comments Sort By Newest

One thought on “ASCO 2016 Update: Immunotherapy and Melanoma

Comments are closed.

    Make An Appointment

    For adults: 877-960-1562

    Quick access: Appointments as soon as the next day for new adult patients

    For children: 888-733-4662

    All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

    Latest Tweets

    Dana-Farber @danafarber
    Stop by booth #132 to learn more about our cellular therapy and stem cell transplant programs! #BMTTandem18 #ASBMT
    Dana-Farber @danafarber
    RT @SusanDFCI: Researchers @DanaFarber, led by Irene Ghobrial, MD, are engaged in a study that may eventually help doctors identify individ…
    Dana-Farber @danafarber
    There’s a lot of information on the Internet about cancer and unfortunately, that includes fiction as well as fact.…

    Republish our posts on your blog

    Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at